TECH — BIO-TECHNE Corp

Nasdaq · Health Care · Biotechnology · CIK 842023 ·
Last close
$47.97
Market Cap
$7.51B
52W High
$62.35
52W Low
$43.12
ADV30
2,958,942
Next earnings
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026
Dec 2025 295,877,000 191,277,000 54,461,000 38,009,000 2,522,699,000 172,879,000 511,710,000
Sep 2025 286,555,000 188,112,000 47,658,000 38,185,000 2,526,148,000 144,962,000 560,334,000
Jun 2025 316,964,000 198,812,000 116,689,000 -17,678,000 2,557,868,000 162,186,000 639,060,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$249,317,000
Investing CF
$-13,783,000
Financing CF
$-251,687,000
CapEx
$-26,297,000
Dividends Paid
$-49,881,000
Buybacks
$-200,127,000
EPS Diluted TTM
$0.69
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$1,106,819,000
Inventory
$205,447,000
Receivables
$184,614,000
ST Investments
EBIT TTM
$83,199,000
Pretax Income TTM
$75,916,000
Interest Exp TTM
$7,283,000
Analysts
11

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,210,811,008
EBITDA
$366,044,992
Free Cash Flow
$299,849,376
Enterprise Value
$7,624,387,584
Total Cash
$214,114,000
Total Debt
$290,321,984
Shares Out
156,568,751
Trailing EPS
$0.70
Book Value
$12.90
ROE
5.3%
ROA
7.5%
Div Yield
0.66%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Jun 2025 1,219,635,000 242,804,000 73,400,000 2,557,868,000 639,060,000 287,556,000
Jun 2024 1,159,060,000 246,401,000 168,105,000 2,703,867,000 635,017,000 298,981,000
Jun 2023 1,136,702,000 290,998,000 285,263,000 2,638,692,000 672,176,000 254,393,000
Jun 2022 1,105,599,000 295,828,000 272,051,000 2,294,805,000 593,794,000 325,272,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$2.06

Peers — same industry

TickerNameMarket CapLastDaily %
QGEN QIAGEN N.V. $7.33B $35.54
PCVX Vaxcyte, Inc. $7.24B $50.11
IMVT Immunovant, Inc. $6.95B $33.83
HALO HALOZYME THERAPEUTICS, INC. $8.15B $68.72
IBRX ImmunityBio, Inc. $8.30B $7.92

News headlines (Yahoo Finance, 1h cache)

Are Wall Street Analysts Bullish on Bio-Techne Stock?
2026-05-25 18:23 · Yahoo
2 Healthcare Stocks to Research Further and 1 We Find Risky
2026-05-23 11:08 · Yahoo
The 5 Most Interesting Analyst Questions From Bio-Techne’s Q1 Earnings Call
2026-05-16 22:52 · Yahoo
Baron Asset Fund Sold Bio-Techne Corporation (TECH) Due to Concerns Over Potential Impact of AI
2026-05-14 14:42 · Yahoo
1 Cash-Producing Stock Worth Investigating and 2 We Turn Down
2026-05-14 01:40 · Yahoo
There May Be Some Bright Spots In Bio-Techne's (NASDAQ:TECH) Earnings
2026-05-13 13:08 · Yahoo
Investment Firm Sells $12.2 Million Worth of Materials Stock, According to Latest SEC Filing
2026-05-12 13:21 · Yahoo
Bio-Techne Q3 Earnings Call Highlights
2026-05-07 06:07 · Yahoo
Why Bio-Techne (TECH) Is Up 5.9% After Profits Rose Despite Slightly Lower Sales – And What's Next
2026-05-06 22:13 · Yahoo
Bio-Techne Corporation Q3 2026 Earnings Call Summary
2026-05-06 20:57 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.